Lexicon Pharmaceuticals vs vTv Therapeutics
LXRX and VTVT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LXRX and VTVT compare
Lexicon Pharmaceuticals is the larger company, worth 12 times as much as vTv Therapeutics ($792M against $68.4M).
vTv Therapeutics grew revenue faster over the last twelve months (216600% versus −29.0% for Lexicon Pharmaceuticals).
vTv Therapeutics keeps more of each dollar of sales as profit, with a net margin of −12.9% compared with −147% at Lexicon Pharmaceuticals.
vTv Therapeutics scores higher on the StockData Score (11 against 5 for Lexicon Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LXRX | VTVT |
|---|---|---|
| Size and price | ||
| Market cap | $792M | $68.4M |
| Share price | $1.78 | $17.29 |
| Change, 1 year | 19.5% | −43.9% |
| Change, 5 years | −62.4% | −67.7% |
| Beta (5Y) | 0.01 | 0.08 |
| Employees | 81 | 26 |
| StockData Score | ||
| Total score | 5 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 2 | 2 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 19.1× | 1.9× (better) |
| P/B | 4.5× | 0.9× (better) |
| Fair value | $0.950 | $44.97 |
| Margin of safety | −87.4% | 61.6% (better) |
| Growth | ||
| Revenue growth (TTM) | −29.0% | 216600% (better) |
| Revenue growth, 5Y average | 15.7% | – |
| Profitability | ||
| Gross margin | 99.1% | – |
| Operating margin | −131% | −25.1% (better) |
| Net margin | −147% | −12.9% (better) |
| Return on equity | −40.2% | −11.7% (better) |
| Return on invested capital | −163% | – |
| Financial health | ||
| Debt / equity | 0.29 (better) | 0.00 |
| Current ratio | 13.37 (better) | 12.48 |
| Altman Z-score | −4.87 | 0.71 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 81.9% | 40.6% |
| Held by insiders | – | 26.3% |
| Insider net buying, 12 months | $2.8M | – |
| Short interest, % of float | – | 5.0% |
Go deeper
- LXRX stock overview
- LXRX income statement
- LXRX valuation and score
- VTVT stock overview
- VTVT income statement
- VTVT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.